We have also previously reported compromised outcomes in patients with constitutive expression of inducible nitric oxide synthase (iNOS), macrophage migration inhibitory factor (MIF) and better outcomes with CD74 expression in stage III melanoma [9,10]. The gene discussed is NOS2; the disease is melanoma.